Factors Associated With Smoking Cessation Attempts in Lung Cancer Screening: A Secondary Analysis of the National Lung Screening Trial.
lung cancer, screening, smoking cessation
Journal
Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
01
11
2021
revised:
25
08
2022
accepted:
26
08
2022
pmc-release:
01
02
2024
pubmed:
27
9
2022
medline:
14
2
2023
entrez:
26
9
2022
Statut:
ppublish
Résumé
Lung cancer remains the leading cause of cancer-related mortality in the United States. The National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer mortality resulting from lung cancer screening (LCS) with an additive reduction from smoking abstinence. However, successful smoking cessation within LCS is variable. What patient and treatment factors are associated with attempts to quit smoking among those screened for lung cancer? In a secondary analysis of the American College of Radiology Imaging Network arm of the NLST, patient demographics, patient smoking behaviors, and tobacco treatment variables were stratified by patient smoking status. The Cox proportional hazards ratio was used to evaluate each variable's effect on attempting to quit smoking. Seven thousand three hundred sixty-nine patients were smoking actively at enrollment in the NLST. Of the patients who reported they were smoking, 73.4% did not receive any pharmacologic tobacco treatment. More patients who attempted to quit received pharmacologic tobacco treatment than those who continued to smoke: (nicotine replacement therapy [NRT], 18.0% vs 12.4% [P < .01]; bupropion, 7.9% vs 6.9% [P = .02]; both NRT and bupropion, 5.6% vs 3.9% [P < .01]). Stable users were more likely to be women (47.8% vs 43.8%; P < .01), to be African American (8.2% vs 6.3%; P = .007), to be unmarried (43.2% vs 36.9% [P < .01]), and to have less than a college education (47.7% vs 42.3%; P < .01). Patients with high dependence who received dual therapy with bupropion and NRT showed the highest likelihood of quit attempt (hazard ratio, 2.07; 95% CI, 1.75-2.44). In this analysis, only one-quarter of patients who underwent LCS and who smoked were treated with pharmacologic therapy, which is associated with increased likelihood of attempting to quit. Certain characteristics are associated with difficulty with attempting to quit smoking. Those with high nicotine dependence benefitted most from dual pharmacologic therapy.
Sections du résumé
BACKGROUND
Lung cancer remains the leading cause of cancer-related mortality in the United States. The National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer mortality resulting from lung cancer screening (LCS) with an additive reduction from smoking abstinence. However, successful smoking cessation within LCS is variable.
RESEARCH QUESTION
What patient and treatment factors are associated with attempts to quit smoking among those screened for lung cancer?
STUDY DESIGN AND METHODS
In a secondary analysis of the American College of Radiology Imaging Network arm of the NLST, patient demographics, patient smoking behaviors, and tobacco treatment variables were stratified by patient smoking status. The Cox proportional hazards ratio was used to evaluate each variable's effect on attempting to quit smoking.
RESULTS
Seven thousand three hundred sixty-nine patients were smoking actively at enrollment in the NLST. Of the patients who reported they were smoking, 73.4% did not receive any pharmacologic tobacco treatment. More patients who attempted to quit received pharmacologic tobacco treatment than those who continued to smoke: (nicotine replacement therapy [NRT], 18.0% vs 12.4% [P < .01]; bupropion, 7.9% vs 6.9% [P = .02]; both NRT and bupropion, 5.6% vs 3.9% [P < .01]). Stable users were more likely to be women (47.8% vs 43.8%; P < .01), to be African American (8.2% vs 6.3%; P = .007), to be unmarried (43.2% vs 36.9% [P < .01]), and to have less than a college education (47.7% vs 42.3%; P < .01). Patients with high dependence who received dual therapy with bupropion and NRT showed the highest likelihood of quit attempt (hazard ratio, 2.07; 95% CI, 1.75-2.44).
INTERPRETATION
In this analysis, only one-quarter of patients who underwent LCS and who smoked were treated with pharmacologic therapy, which is associated with increased likelihood of attempting to quit. Certain characteristics are associated with difficulty with attempting to quit smoking. Those with high nicotine dependence benefitted most from dual pharmacologic therapy.
Identifiants
pubmed: 36162480
pii: S0012-3692(22)03885-5
doi: 10.1016/j.chest.2022.08.2239
pmc: PMC10103689
pii:
doi:
Substances chimiques
Bupropion
01ZG3TPX31
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
433-443Subventions
Organisme : NCI NIH HHS
ID : K07 CA214839
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207229
Pays : United States
Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Références
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Radiol Imaging Cancer. 2020 Aug 21;2(5):e200107
pubmed: 33778737
N Engl J Med. 1999 Mar 4;340(9):685-91
pubmed: 10053177
Tob Prev Cessat. 2021 Jun 29;7:48
pubmed: 34239998
Prev Med. 2016 Nov;92:135-140
pubmed: 27471021
BMJ Open. 2016 Jun 09;6(6):e011045
pubmed: 27288378
Am J Respir Crit Care Med. 2020 Oct 1;202(7):e95-e112
pubmed: 33000953
Nicotine Tob Res. 2020 Mar 16;22(3):307-316
pubmed: 31204787
JAMA. 2006 Jul 5;296(1):47-55
pubmed: 16820546
Am J Respir Crit Care Med. 2015 Oct 1;192(7):881-91
pubmed: 26426785
Nicotine Tob Res. 2007 Nov;9 Suppl 4:S555-70
pubmed: 18067032
Am J Respir Crit Care Med. 2020 Jul 15;202(2):e5-e31
pubmed: 32663106
Ann Am Thorac Soc. 2014 May;11(4):619-27
pubmed: 24701999
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Am J Respir Crit Care Med. 2016 Mar 1;193(5):534-41
pubmed: 26502000
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
J Natl Cancer Inst. 2014 May 28;106(6):dju084
pubmed: 24872540
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Addiction. 1996 Sep;91(9):1271-80; discussion 1281-92
pubmed: 8854358
JAMA. 2014 Jul;312(2):155-61
pubmed: 25005652
Prev Med. 2019 Feb;119:48-51
pubmed: 30576684
Chest. 2018 Jul;154(1):110-118
pubmed: 29793736
MMWR Morb Mortal Wkly Rep. 2017 Jan 06;65(52):1457-1464
pubmed: 28056007
Nicotine Tob Res. 2004 Jun;6(3):447-55
pubmed: 15203778
Am J Respir Crit Care Med. 2018 Jan 15;197(2):172-182
pubmed: 28977754
MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1736-1742
pubmed: 33211681